SCHEDULE: Logos Global Reduces Design Therapeutics Stake, Director Resigns

Logos Global Management LP and affiliated entities updated their beneficial ownership in Design Therapeutics, Inc. to 5.7% following a share sale and the resignation of Dr. Arsani William from the board.

Summary

• Logos Global Management LP and its affiliates, including Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, collectively reported beneficial ownership of 3,255,000 shares of Design Therapeutics, Inc. common stock.
• This represents 5.7% of the outstanding common stock, based on 56,963,757 shares outstanding as of October 31, 2025.
• Logos Global Master Fund LP sold 415,000 shares at $7.25 per share on November 7, 2025.
• Dr. Arsani William resigned from the Issuer's board of directors on September 9, 2025.
• The reporting persons initially acquired 1,217,627 shares from the automatic conversion of preferred stock immediately prior to the Issuer's initial public offering on March 30, 2021.
• Global Fund acquired 2,240,000 shares for a total purchase price of $5,503,042.
• Dr. William was granted options to acquire 15,000 shares of the Stock for his services as a director.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by a key investor group through a share sale and the resignation of their representative from the board. While the remaining stake is still significant, these actions suggest a potential decrease in direct engagement or confidence, which could be viewed negatively by the market.

Positives

• The reporting persons maintain a significant beneficial ownership stake of 5.7% in Design Therapeutics, Inc., indicating continued investment interest.
• Initial acquisition of a substantial block of shares through preferred stock conversion during the IPO suggests early confidence in the company's prospects.

Negatives

• Logos Global Master Fund, L.P. sold 415,000 shares at $7.25 per share on November 7, 2025, reducing the overall stake of the reporting group.
• Dr. Arsani William, a control person of the reporting entities, resigned from the Issuer's board of directors on September 9, 2025, potentially signaling a reduced level of direct influence or engagement.

Risks

• The reporting persons may purchase additional securities or sell all or part of their current holdings at any time, which could impact the stock price.
• They may enter into or unwind hedging or other derivative transactions with respect to the Stock or pledge their interests, potentially affecting market dynamics.
• The reporting persons may recommend additional actions to the Issuer's management, board of directors, and stockholders, which could involve significant corporate events such as mergers, asset sales, changes in control, or other capitalization changes.

Future Outlook

The reporting persons will routinely monitor the Issuer regarding a wide variety of factors, including trading prices, operations, financial position, and strategic matters. They may purchase additional securities, sell existing holdings, enter into hedging transactions, or recommend actions to the Issuer's management and board, potentially including mergers, asset sales, or changes in capitalization.

Management Comments

• "The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations."
• "Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, the reporting persons may recommend additional actions to the Issuer's management, board of directors and stockholders."

Industry Context

This filing primarily details a change in beneficial ownership and a director's resignation specific to Design Therapeutics, Inc. and the reporting entities. It does not provide broader industry trends or competitive analysis.

Management Changes

Stakeholder Impact

• Shareholders: The sale of shares by a significant investor and the resignation of a director could lead to negative market sentiment and potential share price volatility. Future buying or selling activity by the reporting persons could also impact share price.
• Management/Board: The resignation of a director creates a vacancy on the board, potentially requiring a new appointment. The possibility of the reporting persons recommending additional actions could influence strategic decisions.

Next Steps

• Reporting persons will routinely monitor the Issuer's performance and market conditions.
• They may purchase additional securities or sell existing holdings in the open market or privately.
• They may engage in hedging or derivative transactions with respect to the Stock.
• They may communicate with other stockholders, industry participants, and interested parties about the Issuer.
• They may recommend additional actions to the Issuer's management, board, and stockholders, potentially including strategic corporate changes.

Key Dates

Recommendation

While a significant investor has reduced their stake and their representative has resigned from the board, the remaining beneficial ownership of 5.7% is still substantial. The filing indicates the reporting persons will continue to monitor the Issuer and may take further actions, including potentially increasing their stake or recommending strategic changes. This suggests continued, albeit perhaps less direct, engagement. Investors should monitor future actions by Logos Global and the company's performance, but a 'hold' position is warranted given the mixed signals of reduced direct involvement but continued significant ownership.

Keywords

Design Therapeutics, Logos Global Management, Schedule 13D, Beneficial Ownership, Share Sale, Director Resignation, Common Stock, Investment Fund